$49.99
0.75% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$49.99
+13.41 36.66% 1M
+7.10 16.55% 6M
+2.95 6.27% YTD
-4.57 8.38% 1Y
-4.07 7.53% 3Y
+26.82 115.75% 5Y
+42.95 610.09% 10Y
-5.51 9.93% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.37 0.75%

Key metrics

Basic
Market capitalization
$5.9b
Enterprise Value
$5.8b
Net debt
positive
Cash
$858.1m
Shares outstanding
119.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
69.2 | 74.6
EV/Sales
67.7 | 72.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.7%
Return on Equity
435.5%
ROCE
-50.0%
ROIC
-
Debt/Equity
-2.0
Financials (TTM | estimate)
Revenue
$85.7m | $79.6m
EBITDA
$-537.6m | $-667.1m
EBIT
$-547.0m | $-644.3m
Net Income
$-606.3m | $-681.1m
Free Cash Flow
$-438.7m
Growth (TTM | estimate)
Revenue
2,630.6% | 331.1%
EBITDA
-9.0% | -26.7%
EBIT
-8.1% | -20.1%
Net Income
-11.2% | -15.5%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-627.0% | -837.9%
EBIT
-638.0%
Net
-707.2% | -855.5%
Free Cash Flow
-511.7%
More
EPS
$-5.1
FCF per Share
$-3.7
Short interest
16.7%
Employees
498
Rev per Employee
$40.0k
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Cytokinetics, Incorporated forecast:

22x Buy
81%
5x Hold
19%

Analyst Opinions

27 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
81%
Hold
19%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
86 86
2,631% 2,631%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 242 242
34% 34%
282%
- Research and Development Expense 391 391
19% 19%
456%
-538 -538
9% 9%
-627%
- Depreciation and Amortization 9.38 9.38
27% 27%
11%
EBIT (Operating Income) EBIT -547 -547
8% 8%
-638%
Net Profit -606 -606
11% 11%
-707%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
Seeking Alpha
one day ago
Cytokinetics, Incorporated (NASDAQ:CYTK ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executive Vice President of Research & Development Sung Lee - EVP & CFO Isaac Ciechanover - EVP of Corporate Development & Chief Business Officer Conference Call Participants David Lebowitz - Citigroup Inc...
Positive
Seeking Alpha
one day ago
MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies...
Neutral
Seeking Alpha
one day ago
Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital ...
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today